RTN4 (Reticulon 4), also known as Nogo, encodes a family of reticulon proteins with three major isoforms: Nogo-A, Nogo-B, and Nogo-C[1]. RTN4 is most widely recognized for its role as a potent inhibitor of neurite outgrowth and axonal regeneration in the central nervous system (CNS). Nogo-A is expressed primarily in neurons and oligodendrocytes, where it acts through the Nogo-66 receptor (NgR) and its coreceptor LINGO-1 to suppress axon growth after injury[2].
Beyond regeneration inhibition, RTN4 plays critical roles in endoplasmic reticulum (ER) morphology and shaping, vascular development, and cellular stress responses. Dysregulated RTN4 has been implicated in multiple neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and stroke-related neurodegeneration[3].
| Property | Value |
|---|---|
| Gene Symbol | RTN4 |
| Full Name | Reticulon 4 |
| Aliases | NOGO, KIAA0886, NSP |
| Chromosomal Location | 22q11.21 |
| NCBI Gene ID | 57142 |
| OMIM | 604569 |
| Ensembl ID | ENSG00000145113 |
| UniProt ID | Q9NPD4 |
| Gene Type | Protein Coding |
RTN4 produces three major isoforms through alternative splicing and promoter usage:
| Isoform | Amino Acids | Expression | Key Features |
|---|---|---|---|
| Nogo-A | ~1,163 aa | CNS neurons, oligodendrocytes | Contains Nogo-66 loop + unique N-terminal region; potent growth cone collapse |
| Nogo-B | ~373 aa | Ubiquitous; high in vasculature, brain | Shorter isoform; involved in ER morphology and vascular remodeling |
| Nogo-C | ~199 aa | CNS neurons, some peripheral tissues | Shortest isoform; minimal Nogo-66 domain |
The Nogo-66 loop (residues 1059-1160 in Nogo-A) is the critical region for receptor binding and growth cone collapse activity[4]. The N-terminal region of Nogo-A (amino acids 1-1000) is unique to this isoform and has independent growth-inhibitory properties.
All RTN4 isoforms share a C-terminal reticulon homology domain (RHD) consisting of two hydrophobic segments separated by a long loop. This domain localizes the protein to the ER membrane and plays a role in shaping ER tubules and sheets[5].
Nogo-A is the most potent axon growth inhibitor in the CNS[1:1]:
This pathway evolved as a mechanism to stabilize established neural circuits and prevent inappropriate axonal sprouting in adults[2:1].
All RTN4 isoforms contribute to ER network shaping[5:1]:
Nogo-B has distinct roles in vascular biology[3:1]:
In AD, RTN4/Nogo-A has complex, context-dependent roles:
RTN4 involvement in PD includes:
In ALS, RTN4 may contribute to failed axon regeneration:
Nogo-A is most actively targeted in MS research:
After ischemic stroke[6]:
RTN4 expression across tissues:
| Cell Type | Isoform | Expression Level |
|---|---|---|
| Cortical neurons | Nogo-A | High |
| Hippocampal neurons | Nogo-A | High |
| Oligodendrocytes | Nogo-A | Very high |
| Astrocytes | Nogo-A, Nogo-B | Moderate |
| Microglia | Nogo-B | Moderate |
| Vascular endothelium | Nogo-B | High |
| Peripheral tissues | Nogo-B, Nogo-C | Variable |
In the healthy adult brain, Nogo-A is expressed at low basal levels in neurons and sharply upregulated after injury. Nogo-B is constitutively expressed in brain vasculature and some glia.
Multiple therapeutic approaches target Nogo-A[7]:
NgR1 (encoded by RTN4R) is the primary receptor for the Nogo-66 loop[4:1]:
| Protein | Interaction Type | Functional Consequence |
|---|---|---|
| NgR1 (RTN4R) | Receptor binding | Growth cone collapse |
| LINGO-1 | Coreceptor complex | Enhances signal transduction |
| p75^NTR (NGFR) | Coreceptor complex | RhoA activation |
| RhoA | Downstream effector | ROCK activation, cytoskeletal collapse |
| ROCK | Downstream effector | Myosin light chain phosphorylation |
| Oligodendrocyte myelin | Structural | Provides inhibitory substrate |
Key findings from RTN4/Nogo research:
| Agent | Target | Status | Notes |
|---|---|---|---|
| IN-1 (anti-Nogo-A) | Nogo-A | Preclinical | Enhanced regeneration in animal models |
| ATI-355 | Nogo-A | Phase I | Intrathecal delivery in spinal cord injury |
| Opiicinumab (LINGO-1) | LINGO-1 | Phase II (MS) | Did not meet primary endpoints |
| NgR1 decoys | NgR1 | Preclinical | Promising in stroke models |
Schwab ME. Functions of Nogo proteins and their receptors in the nervous system. Nature Reviews Neuroscience. 2010. ↩︎ ↩︎
Pernet V, Schwab ME. The role of Nogo-A in axonal plasticity, regrowth and repair. Cold Spring Harbor Perspectives in Biology. 2012. ↩︎ ↩︎
Acevedo L, et al. Nogo-B: a novel therapeutic target for vascular disease. Nature Reviews Cardiology. 2019. ↩︎ ↩︎
Grandpre T, et al. Nogo-66 receptor antagonist peptide promotes axonal regeneration. Nature. 2000. ↩︎ ↩︎
Peng C, et al. Reticulon 4 deficiency in human disease and murine models. Human Genetics. 2018. ↩︎ ↩︎
Diyora B, et al. Nogo-66 receptor antagonist attenuates tissue plasminogen activator-induced hemorrhage after intracerebral hemorrhage. Neurosurgery. 2011. ↩︎
Oertle T, et al. Nogo-A induces growth cone collapse by interfering with the activity of Rho-associated kinase. Journal of Neuroscience. 2003. ↩︎
Liu BP, et al. Intracellular cues to Nogo-A blockade for axon regeneration. Science. 2003. ↩︎